Dupilumab

ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

Retrieved on: 
Monday, March 11, 2024
Allergy, SAN, Conjunctivitis, Inflammation, EASI, Skin, Data, Cytokine, IGA, Patient, Disease, Dupilumab, ASLN, Pharmaceutical industry

In conjunction with this, independent reviewer confirmation of baseline EASI scores has also been implemented.

Key Points: 
  • In conjunction with this, independent reviewer confirmation of baseline EASI scores has also been implemented.
  • Of the 9 patients who previously had an inadequate response to dupilumab, 5 patients (56%) achieved EASI-90 and 5 patients (56%) a vIGA score of 0 or 1.
  • Additional data from head-to-head studies between eblasakimab and dupilumab in skin biopsies from AD patients confirmed the differentiated effects of targeting IL-13R versus IL-4R5.
  • In this study, eblasakimab reduced localized secretion of pro-inflammatory Type 2 cytokines by the skin tissue more efficiently than dupilumab, suggesting eblasakimab could have the potential to be effective in AD patients that do not achieve an adequate response to dupilumab.

Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, February 22, 2024
Well, Janus, International, Neoplasm, Psoriasis, STAT6, Research, Toxicity, AML, Doctor of Philosophy, ASH, Investment, Blood, Atopic dermatitis, Cash, Growth, Janus kinase, Sale, Lupus, Skin, CTCL, PD-1, Inflammation, Society, JAK, Biomarker, Therapy, Immunology, Hidradenitis suppurativa, Administration, Webcast, Inflammatory bowel disease, Patient, Autoimmunity, Arm, Lymphoma, TYK2, Clinical trial, HS, TPD, G&A, Development, Dupilumab, Phase 1, Human, Pharmaceutical industry

Under the terms of the Sanofi/Kymera collaboration, the dosing of the first patients generated milestone payments totaling $55 million.

Key Points: 
  • Under the terms of the Sanofi/Kymera collaboration, the dosing of the first patients generated milestone payments totaling $55 million.
  • Enrollment in both trials is ongoing, with topline data expected to be reported in the first half of 2025.
  • Kymera unveiled its first-in-class oral STAT6 degrader, KT-621, at its Immunology R&D Day in January.
  • To access the conference call via phone, please dial +1 (833) 630-2127 or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics call.

Press Release: Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee

Retrieved on: 
Tuesday, January 9, 2024
Dupilumab, Culture, Science, Executive Committee, Galderma, GBU, Patient, Head

Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee

Key Points: 
  • Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee
    Paris, January 9, 2024.
  • Brian Foard, a healthcare industry veteran and Sanofi leader in the U.S., has been named Head of the company’s Specialty Care Global Business Unit (GBU).
  • With this appointment, which is effective immediately, Brian becomes a member of Sanofi’s Executive Committee.
  • Brian has been interim Head of the GBU since September 2023 while also serving as Head of Specialty Care North America and U.S. Country Lead.

R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases

Retrieved on: 
Thursday, January 4, 2024
Janus, Atopic dermatitis, Receptor (biochemistry), Sanofi, Janus kinase, Hidradenitis suppurativa, Eosinophilic esophagitis, Autoimmunity, Inflammatory bowel disease, HS, Inflammation, Lupus, Blood, TLR, Therapy, Clinical trial, Asthma, JAK, Dupilumab, Roflumilast, Polyp (medicine), TPD, Webcast, Patient, Psoriasis, TYK2, STAT6, Skin, Sinusitis, Pharmaceutical industry

As part of its strategy, Kymera is unveiling two new programs that each have the potential to address multiple immune-mediated diseases, each with considerable market potential.

Key Points: 
  • As part of its strategy, Kymera is unveiling two new programs that each have the potential to address multiple immune-mediated diseases, each with considerable market potential.
  • Kymera will share its immunology strategy, including market insights, program updates, new preclinical data and development timelines, at its virtual R&D Day this morning.
  • In addition, at low oral doses, KT-621 demonstrated near full in vivo STAT6 degradation and was well-tolerated in multiple preclinical toxicity studies.
  • Kymera will host a webcast to discuss its emerging immunology pipeline from 10:00 a.m. – 12:00 p.m.

Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology

Retrieved on: 
Thursday, December 7, 2023
IRAK4, Dupilumab, Atopic dermatitis, Potential, RSV, Multiple sclerosis, COPD, Research and development, Vaccine, Chronic obstructive pulmonary disease, Asthma, Acne, Growth, Ambition, Webcast, Patient, Development, Fine chemical

Today Sanofi is hosting an Investor R&D Event in New York providing updates and insight into its innovative pipeline and new growth drivers.

Key Points: 
  • Today Sanofi is hosting an Investor R&D Event in New York providing updates and insight into its innovative pipeline and new growth drivers.
  • Sanofi will also share its ambitions to break efficacy ceilings and expand into new indications, generating a steady flow of predominantly wholly-owned new assets.
  • Vaccines - Sanofi reiterates its expectation to generate over €10 billion of annual sales by 2030, including the recent launch of Beyfortus®.
  • With an unprecedented number of potential blockbuster assets in our pipeline, we will showcase how we become a development-driven, tech-powered biopharma company, committed to serving patients and accelerating growth.

Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

Retrieved on: 
Friday, November 10, 2023
Senior, The Carroll School, Serono, Patient, Immunology, Neurology, Oncology, Therapy, Carroll School of Management, Fatty liver disease, Multiple sclerosis, Merck Serono, NASH, Pharmaceutical industry, Nursing, Madrigal, Dupilumab, Sanofi, Boston College, History

CONSHOHOCKEN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Carole Huntsman has been appointed Chief Commercial Officer.

Key Points: 
  • CONSHOHOCKEN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Carole Huntsman has been appointed Chief Commercial Officer.
  • This included executing the launch of Dupixent, a first-in-class therapy which has grown into an industry-leading medicine.
  • In 2022, Ms. Huntsman’s business unit was responsible for over $10 billion in annual net sales.
  • Bill Sibold, Chief Executive Officer of Madrigal, stated, “Carole Huntsman’s leadership skills and experience are a perfect fit for Madrigal as we prepare for a first-to-market launch of resmetirom in the U.S. She has an extensive track record of specialty launch success and excels in building and leading high-performing teams that deliver innovative new therapies to patients with serious diseases.

Bullous Pemphigoid Drug Pipeline Research Report 2023: Comprehensive Insights on 5+ Companies and 5+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Friday, November 10, 2023
Pharmaceutical, Health, Other Health, NDA, Apoptosis, Interleukin 5, AstraZeneca, Neutrophil, Ageing, CH2, Skin, B cell, Clinical trial, Sanofi, Basophil, Macrophage, Patient, FDA, Mergers and acquisitions, Benralizumab, New Drug Application, Therapy, Atopic dermatitis, Regeneron Pharmaceuticals, Drug discovery, Eosinophil, Discovery, News, Dupilumab, Pharmaceutical industry, Vaccine, Health care, Skin condition, Bullous pemphigoid, Phase

The "Bullous Pemphigoid - Pipeline Insight, 2023" report offers comprehensive insights into the pipeline landscape for Bullous Pemphigoid, a skin disorder.

Key Points: 
  • The "Bullous Pemphigoid - Pipeline Insight, 2023" report offers comprehensive insights into the pipeline landscape for Bullous Pemphigoid, a skin disorder.
  • It covers information about more than 5 companies and over 5 pipeline drugs related to Bullous Pemphigoid.
  • Furthermore, the report offers a comprehensive overview of the current status and growth prospects within the Bullous Pemphigoid pipeline landscape.
  • Overall, this report offers a comprehensive and detailed analysis of the Bullous Pemphigoid pipeline landscape, providing valuable insights into the current status and future prospects of potential treatments for this skin disorder.

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 6, 2023
Coordinated Specialty Care, FDA, Non-alcoholic fatty liver disease, Research, Nine Months, Biomarker, Therapy, Cirrhosis, Agency, Treatment, Histology, Priority review, Disease, Hepatology, NASH, Fibrosis, Employee compensation in the United States, Incremental cost-effectiveness ratio, New Drug Application, Intelligence, Diabetes, NAFLD, Atherosclerosis, Fatty liver disease, Electronic health record, Pharmaceutical industry, Cryptocurrency, Medical imaging, Rare-earth element, Risk, Patient, Sanofi, Nature Medicine, Dupilumab, Madrigal

At the AASLD Liver Meeting next week, we will present a comprehensive analysis of noninvasive tests and imaging from the MAESTRO-NASH trial.

Key Points: 
  • At the AASLD Liver Meeting next week, we will present a comprehensive analysis of noninvasive tests and imaging from the MAESTRO-NASH trial.
  • The Agency noted that it is not currently planning to hold an advisory committee meeting to discuss the application.
  • In October 2023, we completed a public offering and received an additional $472.0 million in net cash proceeds.
  • These increases in interest income were due primarily to higher average interest rates in 2023.

ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development Summit

Retrieved on: 
Friday, November 3, 2023
Drug development, Type, AD, Dermatology, Eosinophilic bronchitis, Duke University, Johns Hopkins School of Medicine, Mortality, Cytokine, CCL3, Research, Inflammation, DDDS, Dupilumab, Research fellow, Biology, Constriction, ASLN, Chemokine, Head, AHR, Atopic dermatitis, International Society, Patient, Chronic obstructive pulmonary disease, CCL4, SAN, Pharmaceutical industry, COPD

ASLAN also presented new data investigating the role of eblasakimab in COPD using an established ex vivo model of precision cut lung slices from human donors2.

Key Points: 
  • ASLAN also presented new data investigating the role of eblasakimab in COPD using an established ex vivo model of precision cut lung slices from human donors2.
  • The model tested airway hyperresponsiveness (AHR) in the lung tissue using IL-4 and IL-13, the key Th2 cytokines involved in COPD disease pathology3.
  • Furthermore, IL-4 and IL-13 sensitized the airways to further constriction in response to methacholine, but this sensitization was blocked by eblasakimab treatment.
  • The presentation from Drug Development Summit can be accessed via the ASLAN website here .

Regeneron Reports Third Quarter 2023 Financial and Operating Results

Retrieved on: 
Thursday, November 2, 2023
CSU, DLBCL, Bispecific monoclonal antibody, FDA, Adolescence, American College, Ageing, CD3, ESMO, Food, Multiple myeloma, CD20, Fast Track, ACG, Congress, European Society for Medical Oncology, DME, Symantec Endpoint Protection, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, American College of Gastroenterology, The Lancet, Ministry, Ministry of Health (Kuwait), CRL, MHLW, Ministry of Health, Labour and Welfare, Oncology, Sanofi, Safety, Atopic dermatitis, CSCC, European, Patient, BCMA, Chronic obstructive pulmonary disease, COPD, Dupilumab, BLA, Pharmaceutical industry, Medical device, Vaccine, C5, Regeneron Pharmaceuticals, Health, EU

"Our third quarter financial results reflect robust execution across the enterprise, including notable pipeline advances and strong commercial performance," said Robert E. Landry, Executive Vice President, Finance and Chief Financial Officer of Regeneron.

Key Points: 
  • "Our third quarter financial results reflect robust execution across the enterprise, including notable pipeline advances and strong commercial performance," said Robert E. Landry, Executive Vice President, Finance and Chief Financial Officer of Regeneron.
  • These results were also presented at the 23rd EURETINA Congress in October 2023.
  • The Company announced that Robert E. Landry, Executive Vice President, Finance and Chief Financial Officer of Regeneron, will retire in February 2024.
  • Christopher Fenimore, current Senior Vice President, Head of Accounting and Controller at Regeneron, will succeed Mr. Landry as Chief Financial Officer upon his retirement.